人民同泰盘中涨停，已连收6个涨停板，截至9:26，该股报16.64元，换手率0.32%，成交量186.66万股， 成交金额3106.09万元，涨停板封单金额为2.13亿元。连续涨停期间，该股累计上涨77.21%，累计换手 率为16.08%。最新A股总市值达96.49亿元。 龙虎榜数据显示，该股因连续三个交易日内，涨幅偏离值累计达20%上榜龙虎榜2次，买卖居前营业部 中，营业部席位合计净买入6951.67万元。 据天眼查APP显示，哈药集团人民同泰医药股份有限公司成立于1994年02月19日，注册资本57988.8597 万人民币。（数据宝） 近日该股表现 | 日期 | 当日涨跌幅（%） | 换手率（%） | 主力资金净流入（万元） | | --- | --- | --- | --- | | 2025.11.14 | 10.04 | 7.37 | -12552.10 | | 2025.11.13 | 10.00 | 1.20 | 1466.61 | | 2025.11.12 | 10.04 | 0.82 | 2182.25 | | 2025.11.11 | 9.97 | 1.04 | 3579.93 | | 2 ...

（编辑 楚丽君） 证券日报网讯 11月11日晚间，人民同泰发布公告称，哈药集团人民同泰医药股份有限公司（以下简 称"公司"）股票于2025年11月7日、2025年11月10日、2025年11月11日连续3个交易日内日收盘价格涨幅 偏离值累计超过20%，属于《上海证券交易所交易规则》规定的股票交易异常波动情形。经公司自查， 并向公司控股股东哈药集团股份有限公司、间接控股股东哈药集团有限公司询证，不存在应披露而未披 露的重大事项或重要信息。 ...

Core Viewpoint - The company, Harbin Pharmaceutical Group People's Tongtai Pharmaceutical Co., Ltd., has provided detailed responses to inquiries regarding its financial disclosures, particularly focusing on customer and supplier relationships, accounts receivable, and cash flow management [1][3][6]. Financial Performance - The company's top five customers generated sales of 1.754 billion yuan, accounting for 17.46% of total annual sales, while the top five suppliers had procurement amounts of 1.742 billion yuan, representing 14.85% of total annual purchases [1]. - The end-of-period accounts receivable from the top five debtors amounted to 1.060 billion yuan, making up 24.92% of total accounts receivable [1]. Customer and Supplier Relationships - Major customers in the medical distribution business include public hospitals, private hospitals, community health service centers, and clinics, while suppliers consist of joint ventures and domestic pharmaceutical companies [1]. - The company has identified 47 overlapping customers and suppliers, primarily in the pharmaceutical commercial sector, indicating a need for mutual procurement to meet market demands [2][3]. Accounts Receivable Management - The company has established a dual management standard for credit limits and terms for all credit sales customers, with varying credit periods based on customer type [3]. - The total accounts receivable as of 2024 was 4.256 billion yuan, with a bad debt provision of 202.1 million yuan [3]. Cash Flow and Financial Health - The ratio of cash received from sales to operating income has remained consistent over the past five years, indicating stable cash flow management [4][6]. - The company has implemented measures to control credit risk and improve accounts receivable collection, including a comprehensive management system and regular customer evaluations [3][4]. Other Payables - As of the end of the reporting period, the company reported other payables of 365 million yuan, with significant amounts related to logistics projects and employee settlement fees [8][9]. - The company has clarified that the majority of its other payables are not related to transactions with related parties, ensuring compliance with disclosure requirements [9].

Core Viewpoint - The legal opinion letter from Heilongjiang Huaqian Law Firm confirms the legality of the 2024 annual shareholders' meeting of Harbin Pharmaceutical Group People's Tongtai Pharmaceutical Co., Ltd, including the meeting's convening, attendance, voting procedures, and results [2][3][9]. Group 1: Meeting Procedures - The shareholders' meeting is scheduled for June 26, 2025, at 14:00, held at the company's conference room in Harbin, presided over by Chairman Zhu Weidong [4]. - The meeting will allow for both on-site and online voting, with specific time slots for each voting method [4][6]. Group 2: Attendance and Voting Rights - A total of 434,229,754 shares, representing 74.8816% of the company's total share capital, are eligible for voting [6]. - 186 shareholders and their proxies participated in the online voting, representing 2,859,032 shares, or 0.4930% of the total shares [6]. Group 3: Voting Results - The meeting passed several resolutions with overwhelming support, including: - 436,671,086 shares voted in favor, accounting for 99.9044% of valid votes [7]. - Other resolutions also received similar high approval rates, with votes in favor ranging from 99.7590% to 99.9142% [8][9]. - Special resolutions required a two-thirds majority, while ordinary resolutions needed a simple majority, all of which were met [9].